Literature DB >> 8781572

Mediastinal infusion of epirubicin and 5-fluorouracil. A complication of totally implantable central venous systems. Report of a case.

J M Rodier1, L Malbec, E P Lauraine, L Batel-Copel, A Bernadou.   

Abstract

Perforation of the wall of the superior vena cava by a central venous catheter is reported. The resultant inadvertent infusion of 5-fluorouracil and epirubicin caused a severe acute inflammatory reaction in the right-lobe bronchus, mediastinal infiltration and pleural and pericardial effusions. The patient recovered but has residual mild oesophageal dysfunction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8781572     DOI: 10.1007/bf01213554

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  2 in total

1.  Necrotizing pneumonitis caused by 5-fluorouracil infusion. A complication of a Hickman catheter.

Authors:  F Manheimer; C P Aranda; R L Smith
Journal:  Cancer       Date:  1992-07-15       Impact factor: 6.860

2.  Intrapericardial infusion of 5-fluorouracil. An unusual complication of a Hickman catheter.

Authors:  W F Cathcart-Rake; W E Mowery
Journal:  Cancer       Date:  1991-02-01       Impact factor: 6.860

  2 in total
  3 in total

1.  Central venous port systems as an integral part of chemotherapy.

Authors:  Ulf K Teichgräber; Robert Pfitzmann; Herbert A F Hofmann
Journal:  Dtsch Arztebl Int       Date:  2011-03-04       Impact factor: 5.594

2.  Mediastinal extravasation of doxorubicin.

Authors:  Teresa Quintanar Verdúguez; Adolfo Blanco Jarava; María Blanca Martínez-Barbeito; Cristina Pangua Méndez; Luis López Gómez; Jesús Andrade Santiago; Ignacio Chacón López-Muñiz
Journal:  Clin Transl Oncol       Date:  2008-02       Impact factor: 3.405

3.  Intrapulmonal dislocation of a totally implantable venous access device.

Authors:  Thilo Hackert; Christin Tjaden; Angelika Kraft; Bernd Sido; Hendrik Dienemann; Markus W Buchler
Journal:  World J Surg Oncol       Date:  2005-04-11       Impact factor: 2.754

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.